OSLI Retina

October 2016

Issue link: http://osliretina.healio.com/i/737622

Contents of this Issue

Navigation

Page 12 of 95

October 2016 · Vol. 47, No. 10 899 Practical Retina 2014;2014:273506. 17. Lasave AF, Díaz-llopis M, Muccioli C, Belfort R, Arevalo JF. In- travitreal clindamycin and dexamethasone for zone 1 toxoplas- mic retinochoroiditis at twenty-four months. Ophthalmology. 2010;117(9):1831-1838. 18. Baharivand N, Mahdavifard A, Fouladi RF. Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic reti- nochoroiditis: a prospective randomized clinical trial. Int Ophthal- mol. 2013;33(1):39-46. 19. Gagliuso DJ, Teich SA, Friedman AH, Orellana J. Ocular toxoplas- mosis in AIDS patients. Trans Am Ophthalmol Soc. 1990;88:63-86; discussion 86-88. 20. Butler NJ, Furtado JM, Winthrop KL, Smith JR. Ocular toxoplas- mosis II: clinical features, pathology and management. Clin Experi- ment Ophthalmol. 2013;41(1):95-108. 21. Felix JP, Lira RP, Zacchia RS, Toribio JM, Nascimento MA, Arieta CE. Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of Toxoplasma gondii retinochoroiditis: random- ized controlled clinical trial. Am J Ophthalmol. 2014;157(4):762- 766.e1. 22. Jasper S, Vedula SS, John SS, Horo S, Sepah YJ, Nguyen QD. Cor- ticosteroids as adjuvant therapy for ocular toxoplasmosis. Cochrane Database Syst Rev. 2013;(4):CD007417. 23. Rush R, Sheth S. Fulminant toxoplasmic retinochoroiditis follow- ing intravitreal triamcinolone administration. Indian J Ophthalmol. 2012;60(2):141-143. 24. Oray M, Ozdal PC, Cebeci Z, Kir N, Tugal-Tutkun I. Fulminant ocular toxoplasmosis: the hazards of corticosteroid monotherapy. Ocul Immunol Inflamm. 2015;8:1-10. 25. O'Connor GR, Frenkel JK. Editorial: Dangers of steroid treatment in toxoplasmosis. Periocular injections and systemic therapy. Arch Ophthalmol. 1976;94(2):213. Samuel P. Burke, MS, can be reached at Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, Miller School of Medicine, 900 N.W. 17th Street, Miami, FL 33136; email: to samburke@ med.miami.edu. Howard F. Fine, MD, MHSc, can be reached at NJ Retina, 10 Plum Street, Suite 600, New Brunswick, NJ 08901; email: hffine@gmail.com. Thomas A. Albini, MD, can be reached at Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, Miller School of Medicine, 900 N.W. 17th Street, Miami, FL 33136; email: talbini@med. miami.edu. Disclosures: Dr. Fine is a consultant for Allergan, Genentech, and Regen- eron and has patent and equity interest in Auris Surgical Robotics. The remaining authors have no relevant financial disclosures.

Articles in this issue

Links on this page

Archives of this issue

view archives of OSLI Retina - October 2016